Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells
Open Access
- 1 February 2020
- journal article
- research article
- Published by Elsevier in EBioMedicine
- Vol. 52, 102633
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
This publication has 59 references indexed in Scilit:
- Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brainOrphanet Journal of Rare Diseases, 2013
- A possible cranio-oro-facial phenotype in Cockayne syndromeOrphanet Journal of Rare Diseases, 2013
- Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in miceHepatology, 2011
- Peroxisome Proliferator-activated Receptor γ Co-activator 1α (PGC-1α) and Sirtuin 1 (SIRT1) Reside in MitochondriaJournal of Biological Chemistry, 2010
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyNephrology Dialysis Transplantation, 2009
- Differential Activation of Multiple Signalling Pathways Dictates eNOS Upregulation by FGF2 but not VEGF in Placental Artery Endothelial CellsPlacenta, 2008
- Integrins in angiogenesis and lymphangiogenesisNature Reviews Cancer, 2008
- Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined FactorsCell, 2007
- Establishment and characterization of Fabry disease endothelial cells with an extended lifespanMolecular Genetics and Metabolism, 2007
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006